VERTEX PHARMAC. DL-,01 financial statements, including revenue, expenses, profit, and loss

The total revenue of VX1 for the last quarter is 2.49 B EUR, and it's 1.32% higher compared to the previous quarter. The net income of Q3 24 is 938.92 M EUR.